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Abstract 
Purpose: To design and develop halogenated chalcone derivatives and evaluate them as anticancer 
agents using different cancer cell lines. 
Methods: Based on in silico design and docking on known target, crystal structure of the complex of 
interleukin-1beta converting enzyme (ICE) with a peptide based inhibitor, (3S )-N-Methanesulfonyl-3-
({1-[N-(2-naphtoyl)-l-valyl]-l-prolyl}amino)-4-oxobutanamide (1BMQ), novel halogenated chalcone 
derivatives were designed (7a-h) employing LigandFit module of Accelrys (Discovery Studio, 2.1 
version). Standard protocols for ligand and protein preparation were employed and their binding 
orientation validated using (3S)-N-Methanesulfonyl-3-({1-[N-(2-naphtoyl)-l-valyl]-l-prolyl}amino)-4-
oxobutanamide (MNO 601), a caspase inhibitor as reference standard. Energy minimized conformers 
with best dock scores were considered for the identification of interacting amino acid residues with 
ligands. Selected derivatives were synthesized and analyzed by melting point, 1H NMR, IR and mass 
spectroscopy. Their evaluation for anticancer activity was carried out using adriamycin, paclitaxel and 5-
fluorouracil as reference standards on prostrate (PC-3), colon (COLO-205), ovary (OVCAR-5), liver 
(HEP-2) and neuroblastoma (IMR-32) cancer cell lines, and % growth inhibition and half maximal 
inhibitory concentration (IC50) values were calculated. 
Results: Among synthesized compounds, 7b showed the most promising cytotoxic activity with an IC50 
of 49.9 µM on colon cancer cell lines (Colo-205), followed by 7d with an IC50 of 66.6 µM against ovarian 
cancer cell lines (OVCAR-5). 
Conclusion: We report the successful synthesis, spectral characterization and in vitro anticancer 
evaluation of a series of novel halogenated chalcone derivatives against a number of human cancer cell 
lines. The findings indicate the emergence of new anticancer compounds. 
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Chalcones constitute one of the important 
classes of anticancer agents that have shown 
promising therapeutic efficacy in the 
management of human cancers. They are 
considered as the precursors of flavonoids and 
isoflavonoids and are abundantly available in 
edible plants. They show a wide variety of 
activities, including anticancer [1], anti-
Jain et al 
Trop J Pharm Res, January 2014;13 (1): 
 
74 
inflammatory [2] and antiparasitic [3] activities. A 
number of modifications on chalcone 
chromophore have been reported including 
hydroxyl [4], methoxy [5], and amino [6] groups 
as substituents with promising anticancer activity.  
 
A series of 4-hydroxy-6-methoxyaurones and 4, 
6-dimethoxyaurones, which have binding affinity 
toward the nucleotide-binding domain of P-
glycoprotein, an ABC (ATP-binding cassette) 
transporter that mediates the resistance of 
cancer cells to chemotherapy, have been 
synthesized [7]. These compounds differ by the 
nature of the substituent on the aurone B-ring. 
The most active compounds were halogenated 
aurones: 4’-bromo-4-hydroxy-6-methoxyaurone 













   
Further, they reported a strategy of opening ring 
B to generate diaryl chalcones and succeeded in 
getting 2’,4’,6’-trihydroxy-4-iodochalcone (3) with 
higher affinity with a KD value in nanomolar range 
[8]. 
 
A number of chalcone derivatives have been 
evaluated for multidrug resistance (MDR) 
reversal activity on mouse lymphoma cells and it 
was found that their activity decreased when the 
hydrophobicity of the substituent on ring B was 
lowered, it is usually at 4-position (para to the 
carbonyl group) and the rank order of activity 
was found to be: chloro > dimethylamino > 
methoxyl group. One of them (4) exhibited 







These observations prompted us to design and 
synthesize halogenated chalcone derivatives  
based on in silico modeling and docking on 
known target 1BMQ and evaluated for their 





Molecular modeling was performed using Dell 
Precision work station T3400 running Intel Core2 
Duo Processor, 4GB RAM, 250 GB hard disk, 
and NVidia Quodro FX 4500 graphics card. The 
software tool employed for the study was 
LigandFit module of Accelrys (Discovery Studio 
2.1 version) [10]. 
 
Materials and equipment 
 
Starting materials, reagents and solvents were 
purchased from commercial suppliers and 
purified/distilled/crystallized before use. All the 
melting points were recorded in open glass-
capillaries on a Veego MP-D digital melting point 
apparatus and are uncorrected. Bruker Avance II 
(400 MHz) Nuclear Magnetic Resonance (NMR) 
spectrometer was used to record 1H spectra. 
Chemical shifts (δ) are reported as downfield 
displacements from Tetramethylsilane (TMS) 
used as internal standard. Infrared (IR) spectra 
were recorded with Shimadzu FT-IR-8400S 
spectrophotometer on KBr pellets. Mass spectra 
(ESI-method), were recorded on Bruker 
Daltonics Esquire 300 mass spectrometer.  
 
Molecular modeling studies 
 
Design of ligands 
 
The design of the target molecules was based on 
docking studies with the intention to gain an 
insight into the binding mode of the most active 




It can be described as two components: a search 
strategy and an evaluation of docking results 
(scoring function). The search algorithm 
generates optimum number of poses including 
experimentally determined binding mode. The 
docked poses were scored using Dock score 
(Accelrys) to find the better docking pose. 
 
Preparation of proteins 
 
Docking was carried out against caspase-1 
protein (1BMQ) which is the possible anticancer 
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Figure 1: Scheme of synthesis 
 
target protein was retrieved from Protein Data 
Bank (PDB) [13]. 
 
All ligands, bound water molecules and co-
factors were removed from the proteins which 
were taken in .pdb format. CHARMm force field 
[14] for minimization of the protein {(steepest 
descent (gradient < 0.1) and conjugate gradient 
algorithms (gradient < 0.01)}. An appropriate 
active-site was defined to constitute amino acid 
residues (PDB: 1BMQ) of 10 Å from the centroid 
of the bound ligand (if required, partitioned up to 
5 levels). Stochastic conformational searching 
was applied to the ligands with a number higher 
than the default number of Monte Carlo search 
steps, to ensure extensive conformational 
sampling. 
 
Preparation of ligands 
 
2-D Structures of the ligands were imported by 
sketching the structures from Chem Draw Ultra - 
5.0 version [15]. The ligands were minimized by 
CHARMm Force Field with default setting. 
‘Prepare Ligands’ module was used for the final 
preparation of ligands for docking run.    
 
Ligand Fit docking 
 
Ligand Fit (a shape-based method) employs a 
cavity detection algorithm. A shape comparison 
filter was combined with Monte Carlo technique 
to generate ligand conformations which were 
then docked into the active-site of a protein. 
Caspase-1 protein was chosen as a target for 
docking because the sensitivity of U937 
monocytic cells to apoptosis induced by 
etoposide and that the apoptotic process 
involves the activity of members of the caspase-1 
subfamily [16-19]. 
 
A grid resolution was set at 0.5 Å (default). The 
ligand-accessible grid was defined such that the 
minimum distance between a grid point and the 
protein is 2.0 Å for hydrogen and 2.5 Å for heavy 
atoms. The grid extended from the defined active 
site to a distance of 5 Å in all directions. This grid 
was used to calculate the non-bonded 
interactions between the ligands and protein 
residues. Non-bonded cutoffs were set at 10 Å 
while using a distance-dependent dielectric 
constant. Ten iterations of minimization were 
performed before considering the next iterations 
and the selected conformers were minimized 
further to 100 iterations. The ligand 
conformational space was explored with different 
initial poses. To avoid identical conformations, 
RMSD cutoff of 1.5 and a score cutoff of 20 
Kcal/mol were maintained while recording the 
final conformations. Docking run generated 10 






Acetophenone (5) 1.1 mol was dissolved in 
ethanol with stirring and ethanolic KOH (6 mol) 
was added to this solution at 0 0C. The mixture 
was stirred for 10-30 min followed by the addition 
of 1 mol of the appropriate aldehyde (6). The 
completion of the reaction was monitored by TLC 
(CHCl3:CH3OH, 95:5) and the disappearance of 
aldehyde spot was considered as completion of 
the reaction. The solid was separated from the 
reaction mixture as a precipitate, filtered and re-
crystallized using rectified spirit to obtain pure 




In vitro cytotoxicity against human cancer cell 
lines 
 
The human cancer cell lines were procured from 
National Cancer Institute, Frederick, U.S.A. The 
cells were grown in tissue culture flasks in 
complete growth medium (RPMI-1640 medium 
with 2mM glutamine, pH 7.4, supplemented with 
10 % fetal calf serum, 100 µg/ml streptomycin 
and 100 units/ml penicillin) in a carbon dioxide 
incubator (37 °C, 5 % CO2, 90 %RH). The cells 
at subconfluent stage were harvested from the 
flask by treatment with trypsin {0.05 % in PBS 
+ 
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(pH 7.4) containing 0.02% EDTA}. Cells with 
viability of more than 98 %, as determined by 
trypan blue exclusion, were used for the 
determination of cytotoxicity. The cell suspension 
of 1 x 105 cells/ml was prepared in complete 
growth medium. 
 
Stock solutions (2 x 10-2 M) of compounds 7a-h 
were prepared in Dimethyl sulfoxide (DMSO). 
The stock solutions were serially diluted with 
complete growth medium containing 50 µg/ml of 
gentamycin to obtain working test solutions of the 
required concentrations. 
 
In vitro cytotoxicity against five human cancer 
cell lines was determined using 96-well tissue 
culture plates. Cell suspension (100 µL) was 
added to each well of the 96-well tissue culture 
plate. The cells were allowed to grow in carbon 
dioxide incubator (37 °C, 5 % CO2, 90 %RH) for 
24 h. Test materials in complete growth medium 
(100 µL) were added after 24 h of incubation to 
the wells containing cell suspension. The plates 
were further incubated for 48 h in a carbon 
dioxide incubator. The cell growth was stopped 
by gently layering trichloroacetic acid (50 %, 50 
µL) on top of the medium in all the wells. The 
plates were incubated at 4 oC for one hour to fix 
the cells attached to the bottom of the wells. The 
liquid of all the wells was gently pipetted out and 
discarded. The plates were washed five times 
with distilled water to remove trichloroacetic acid, 
growth medium, low molecular weight 
metabolites, serum proteins, etc, and air-dried. 
The plates were stained with sulforhodamine B 
dye (0.4 % in 1 % acetic acid, 100 µL) for 30 min. 
The plates were washed five times with 1 % 
acetic acid and then air-dried. The adsorbed dye 
was dissolved in Tris-HCl buffer (100 l, 0.01M, 
pH 10.4) and the plates were gently stirred for 10 
min on a mechanical stirrer. The optical density 
(OD) was recorded on an ELISA reader at 540 
nm. 
 
The cell growth was determined by subtracting 
the mean OD value of the respective blank from 
the mean OD value of the experimental set. 
Growth (%) in the presence of the test material 
was calculated, considering the growth in the 
absence of any test material as 100 %; in turn, 
growth inhibition (%) in the presence of the test 




Values reported are the mean values of three 
experiments each carried in triplicate. IC50 values 
were calculated using non-linear regression 
analysis with the aid of Prism (GraphPad Inc, 
USA). P < 0.05 was considered statistically 






Energy minimized conformer with best Dock 
scores (Table 1) was considered for the 
identification of interacting amino acid residues 













Table 1: Docking studies of halogenated chalcones 
  
Compound R1  R2  R3  R4  R5  R1'  R2'  R3'  R4'  R5'  
1BMQ 
Dock 
score   
Standard  (MNO601)                        57.5 
7a H H  Br  H H OCH3 H  OCH3 H  H 48.5 
7b H H  OC6H5  H H F  H  H  H  OCH3 48.6 
7c H  H  Br  H  H  Cl  OCH3  OCH3  H  Cl  51.87 
7d H  H  OCH3  H  H  Br  H  H  OCH3  H  49.62 
7e H  H  OC6H5  H  H  H  H  OCH3  H  F  48.71 
7f H  H  Br  H  H  OCF3  H  H  H  H  47.3 
7g H  H  Br  H  H  Br  H  H  OCH3  H  46.05 
7h H  H  OCH3  H  H  Cl   OCH3  OCH3  H  Cl  49.39 
7i H  H  H  H  OCH3  H  OC2H5  H  H  Cl  47.3 
7j H  H  H  H  H  H  H  H  H  Br 38.32 
7k H  H  H  H  H  H  H  H  H  H  35.89 
7l H  H  Br H  H  H  H  H  H  H  37.36 
7m H  H  Cl H  H  H  H  H  H  H  36.62 
7n H  H  H  H  H  H  Cl H  H  H  37.73 
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In the present investigation eight new chalcone 
derivatives (7a-h) were prepared by the Claisen–
Schmidt condensation of different ketones (5) 
and appropriately substituted aldehydes (6) using 
reported method (Figure 1, Table 2) [20]. 
 
The compounds were re-crystallized using 
rectified spirit. All the compounds were 
characterized by detailed spectroscopic (IR, 1H 
NMR, Mass) analyses. 
 




(min) Yield (%) 
7a 16 94 
7b 24 93 
7c 12 90 
7d 17 90 
7e 30 89 
7f 25 92 
7g 13 82 
7h 28 87 
 
1-(4-Bromo-phenyl)-3-(2,4-dimethoxy-phenyl)-
propenone (7a)  
 
Yellow solid, m.p.: 89-910C, IR (KBr) 2852, 1652, 
1463, 1453, 967 cm_1; 1H NMR (CDCl3, 400 
MHz, δ, ppm) 3.90 (3H, s, OCH3), 3.86 (3H, s, 
OCH3),  6.4 (1H, d, Ar), 6.5 (1H, dd, Ar), 7.4 (1H, 
d, Ar), 7.5 (1H, d, =CH-CO-), 7.6 (2H, d, Ar), 7.8 
(2H, d, Ar),  8.0 (1H, d, =CH-Ar); MS (ESI, m/z) = 





Light yellow solid, m.p.: 92-95 0C, IR (KBr) 2951, 
2851, 1659, 1462, 1454, 972 cm_1; 1H NMR 
(CDCl3, 400 MHz, δ, ppm) 3.8 (3H, s, OMe), 6.65 
(2H, m, Ar), 7.01 (4H, m, Ar), 7.1 (1H, d, =CH-
CO-), 7.2 (4H, m, Ar), 7.8 (1H, d, =CH-Ar), 7.97 





Yellow solid, m. p.: 155-157 0C, IR (KBr) 2923, 
2853,1664, 1490, 1458, 974, 960 cm_1; 1H NMR 
(CDCl3, 400 MHz, δ, ppm) 3.7 (3H, s, OMe), 3.85 
(3H, s, OMe), 6.9 (1H, s, Ar), 7.56 (1H, d, =CH-
CO-), 7.64 (2H, d, Ar), 7.78 (2H, d, Ar), 7.81 (1H, 
d, =CH-Ar) ; MS (ESI, m/z) = 416 (M++1) (63%), 




Yellow solid, m.p.: 121-123 0C, IR (KBr)  2922, 
2852, 1658, 1462, 1455, 968 cm_1; 1H NMR 
(CDCl3, 400 MHz, δ, ppm), 3.85 (3H, s, OMe), 
3.89 (3H, s, OMe), 6.81 (1H, dd, Ar), 6.97 (2H, d, 
Ar),7.23 (1H, d, =CH-CO-), 7.38 (1H, d, Ar), 7.51 
(1H, d, Ar), 8.01 (1H, d, =CH-Ar), 8.06 (2H, d, Ar) 






Yellow solid, m.p.: 125-127 0C, IR (KBr) 2972, 
2942, 2881, 2837, 1680, 1657, 1585, 1488, 
1469, 988 cm_1; 1H NMR (CDCl3, 400 MHz, δ, 
ppm), 3.85 (3H, s, OMe), 6.65 (2H, m, Ar), 7.01 
(4H, m, Ar), 7.1 (1H, d, =CH-CO-), 7.2 (4H, m, 
Ar), 7.8 (1H, d, =CH-Ar), 7.94 (2H, m, Ar) ; MS 





Yellow solid, m.p.: 180-183 0C, IR (KBr) 2852, 
1654, 1596, 1552, 1462, 1455, 1376, 1306, 
1154, 1078, 966 cm_1; 1H NMR (CDCl3, 400 
MHz, δ, ppm), 7.13 (1H, d, Ar), 7.17 (1H, d, =CH-
CO), 7.38 (1H, m, Ar), 7.47 (2H, m, Ar), 7.57 (1H, 
d, =CH-Ar), 7.8 (2H, m, Ar), 7.95 (2H, m, Ar) ; 






Yellow solid, m.p.: 192-194 0C, IR (KBr) 2842, 
1678, 1582, 1481, 1394, 1245, 1072, 1014, 817 
cm_1; 1H NMR (CDCl3, 400 MHz δ, ppm), 3.85 
(3H, s, OMe), 6.81 (1H, dd, Ar), 6.97 (2H, d, 
Ar),7.23 (1H, d, =CH-CO-), 7.38 (1H, d, Ar), 7.51 
(1H, d, Ar), 8.01 (1H, d, =CH-Ar), 8.06 (2H, d, Ar) 






Yellow solid, m.p.: 131-133 0C, IR (KBr) 2945, 
2877, 2837, 1669, 1606, 1490, 1434, 961 cm_1; 
1H NMR (CDCl3, 400 MHz, δ, ppm), 3.57 (3H, s, 
OMe), 3.7 (3H, s, OMe), 3.85 (3H, s, OMe), 6.9 
(1H, s, Ar), 7.56 (1H, d, =CH-CO-), 7.59 (2H, d, 
Ar), 7.78 (2H, d, Ar), 7.81 (1H, d, =CH-Ar) ; MS 
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The in vitro cytotoxic activity of compounds 7a-h 
are reported in terms of % inhibitory 
concentration (IC50) and the data are shown in 
Table 3. 
 
The synthesized compounds showed good 
anticancer activity against colon and ovarian 
cancer cell lines. The results of anticancer 
activity revealed that in the case of colon cell line 
(COLO-205), the maximum inhibition 71% (50 
µM) was observed for 7b with IC50 = 49.9 
followed by 37 % and 36 % for 7d and 7a at the 
same concentration. For ovarian cancer cell line 
(OVCAR-5) also the maximum inhibition 42 % 
(50 µM) and 39 % (10 µM) were observed for 7d 
(IC50 = 66.6), followed by 38 % at the same 
concentration for 7a. 
 
Against liver cell line (HEP-2) the maximum 
inhibition of 32% (50 µM) and 31% (50 µM) for 
7b and 7d were observed. The inhibitory effect 
on CNS was also evaluated using (IMR-32) cell 
lines. In this case maximum inhibition of 35 % for 
7d and 30 % for 7c (50 µM) were observed. In 
the case of prostate cancer cell line (PC-3) none 
of the compounds showed significant activity. 
Compounds 7b and 7d, however, exhibited 11 % 




In the present investigation, in silico docking 
studies were performed using the crystal 
structure of interleukin-1beta convertase 
(caspase-1) (PDB ID: 1BMQ) [13, 21] to 
recognize the hypothetical binding mode of the 
ligands with the receptor in order to design a 
series of novel halogenated chalcone derivatives 
(7a-h) as possible anticancer agents. To 
investigate the ability of molecular docking to 
 
Table 3: In vitro cytotoxicity including IC50 values of compounds 7(a-h) against different human cancer cell lines 
 
Compound Conc. / % Growth inhibitiona / IC50 b 
  IC 50 (μM) PC-3 Colo-205 OVCAR-5 Hep-2 IMR-32 
 
7a 10 0 20 22 9 0 
 50 8 36 38 19 0 
 IC50 >100 >100 >100 >100 >100 
7b 10 2 20 33 22 9 
 50 11 71 34 32 25 
 IC50 >100 49.9 >100 >100 >100 
7c 10 1 32 11 16 8 
 50 3 33 21 19 30 
 IC50 >100 >100 >100 >100 >100 
7d 10 6 18 39 7 9 
 50 11 37 42 31 35 
 IC50 >100 >100 66.56 >100 >100 
7e 10 2 13 36 13 9 
 50 2 18 37 15 13 
 IC50 >100 >100 >100 >100 >100 
7f 10 2 19 16 5 11 
 50 5 22 24 7 20 
 IC50 >100 >100 >100 >100 >100 
7g 10 0 6 24 7 0 
 50 6 10 34 11 20 
 IC50 >100 >100 >100 >100 >100 
7h 10 1 7 20 15 0 
 50 1 9 22 23 9 
 IC50 >100 >100 >100 >100 >100 
Adriamycin 10 73 81 79 86 47 
Paclitaxel 10 10 78 53 54 21 
5 FU 2 9 39 32 10 11 
a % inhibition caused by the compounds and standard drugs at various concentrations. 
b 50 % inhibitory concentration represents the mean from dose response curves of number of experiments 
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reproduce an experimentally observed ligand 
binding mode, the co-crystallized ligand MNO 
601 (3s)-n-methanesulfonyl-3-({1-[n-(2-naphtoyl)-
l-valyl]-l-prolyl}amino)-4-oxobutanamide has 
been used as reference ligand (IC
50 
= 38 nM). 
Subsequently, MNO 601 was docked back into 
its binding site of the crystal structure of the 
caspase-1 using Discovery Studio, Version 21 
(2007), Accelrys Inc. [10].  
 
The docking pose closely resembled the co-
crystallized conformation. The naphthyl group 
showed significant π-stacking interaction with 
His342 and Arg383 that was proposed to be 
crucial for having the enhanced binding affinity of 
the co-crystal ligand [21]. The carbonyl oxygen 
atom formed a strong hydrogen bond with the 
side chains of Arg341 at a distance 2.70 Å. 
Moreover, the nitrogen atom of the amide group 
seems to be deprotonated and have a salt bridge 
with Arg341. The oxygen atom of methanesul-
fonaminocarbonyl group was found to form a 
hydrogen bond with the nitrogen atom of 
guanidine moiety of Arg341 and pyrazole ring of 
His237 at a distance of 2.47 and 3.10 Å 
respectively. The aldehyde group of the ligand 
formed strong covalent bond with the sulphur 
atom of Cys285. All the designed compounds 
were docked following the same docking protocol 
and analyzed for their interactions with the 
binding site (active site) amino acids of caspase-
1. Binding orientation of the most active 




Figure 2: Binding orientation of the most active 
compound (7b) 
 
The designed compounds were found to 
accommodate the binding pocket of the receptor 
showing the important interactions with the 
crucial amino acid residues. In particular, the O-
methoxy moiety was found to form a significant 
hydrogen bond interaction with His237 and 
Arg341 at a distance of 3.0 Å and 1.9 Å 
respectively. Interestingly, no salt bridge 
formation was observed with the designed 
compounds. The fluoro group of the phenyl ring 
formed crucial hydrogen bond with Arg341. 
Weak hydrogen bond is also observed between  
phenyl ring and Cys 285. Additional interaction 
with Ser339 was also seen.  
 
All the compounds with predicted good binding 
affinities (docking score) as compared to the 
reference standard (MNO 601) (Table-1) were 
selected for synthesis (Figure 1, Table 2) and 
later on evaluated for anticancer activity. The 
synthesized compounds showed good anticancer 
activity against colon and ovarian cancer cell 
lines. The in vitro results (Table 3) showed that 
these molecules may potentially be used for 
targeting caspase-1 for the management of 
cancer expressing caspase dependent apoptosis 
pathway. Therefore, the synthesized compound, 
3-(2-Fluoro-6-methoxy-phenyl)-1-(4-phenoxy-
phenyl)-propenone (7b) may possess essential 
candidature to be studied in vivo for proving 




The new halogenated chalcones designed and 
synthesized, based on the bioisosteric 
replacement of a known ligand, were well docked 
onto the binding pocket of caspase enzyme and 
interacted with crucial amino acid residues. 
Compounds 7a, 7b, 7d are active on colon 
cancer line COLO-205, and 7b showed IC50 
value of 49.9. These molecules may serve as 
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